Search tips
Search criteria 


Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
Cancer Res. Author manuscript; available in PMC 2012 December 1.
Published in final edited form as:
PMCID: PMC3228897

Dishevelled 2 signaling promotes self-renewal and tumorigenicity in human gliomas


Glioblastoma multiforme is the most common glioma variant in adults and is highly malignant. Tumors are thought to harbor a subpopulation of stem-like cancer cells, with the bulk resembling neural progenitor-like cells that are unable to fully differentiate. Although multiple pathways are known to be involved in glioma tumorigenesis, the role of Wnt signaling has been poorly described. Here we show that Dishevelled 2 (Dvl2), a key component of the Wnt signaling pathway, is overexpressed in human gliomas. RNAi-mediated depletion of Dvl2 blocked proliferation and promoted the differentiation of cultured human glioma cell lines and primary, patient-derived glioma cells. In addition, Dvl2 depletion inhibited tumor formation after intra-cranial injection of glioblastoma cells in immunodeficient mice. Inhibition of canonical Wnt/β-catenin signaling also blocked proliferation, but unlike Dvl2 depletion, did not induce differentiation. Finally, Wnt5a, a non-canonical Wnt ligand,was also required for glioma cell proliferation. The data therefore suggest that both canonical and non-canonical Wnt signaling pathways downstream of Dvl2 cooperate to maintain the proliferative capacity of human glioblastomas.

Keywords: glioma, cancer stem cell, Wnt signaling, Dishevelled, differentiation


Glioblastoma multiforme (GBM) is a lethal brain tumor, with most patients dying within one year of diagnosis (1, 2). The last decade has witnessed very little advance in treatment, but the identification of stem-like cancer cells in brain tumors has provided new insights into the disease. Several groups have identified a sub-population of stem-like, cancer cells in brain tumors, using biomarker analysis and culturing techniques similar to those used to characterize normal neural stem cells. These cells demonstrate a significant tumor-initiating ability, are capable of self-renewal, and express neural stem cell markers, such as Nestin and CD133, but not markers of the differentiated neural lineage (3-7). Although these cells represent only a small fraction of the tumor bulk, their high self-renewal capacity is thought to sustain tumor growth. The identification of signaling pathways that maintain the proliferative capacity of these cells and/or regulate their decision to differentiate offers great potential for a better understanding of the disease at the molecular level.

For neural stem cells, the decision to divide or differentiate is strongly influenced by Wnt signaling, while other factors, such as EGF and FGF, stimulate their proliferation (8-10). Wnt ligands are capable of activating several distinct signal transduction pathways and promoting a large spectrum of cellular processes, such as proliferation, differentiation, polarity, adhesion and migration (11, 12). Wnt signaling pathways are usually categorized as canonical, or non-canonical. The former describes the classical β-catenin/gene transcription pathway, while the latter is most often linked with polarity establishment and cytoskeleton-mediated processes, but can also involve gene transcriptional effects (though not through β-catenin). The scaffold protein Dishevelled (Dvl) plays an essential role in all known Wnt signaling pathways. Activation of canonical Wnt signaling recruits Dvl to the plasma membrane, resulting in the disassembly of the ß-catenin destruction complex and leading to the translocation of active ß-catenin to the nucleus, with subsequent activation of gene expression. Activation of non-canonical Wnt pathways leads to Dvl-mediated activation of Rho GTPases, planar cell polarity proteins, and Ca2+-dependent signals (13-17). In order to discriminate between canonical or non-canonical pathways, Wnt signaling utilizes different domains of Dvl to activate distinct downstream components. In particular, the DIX domain is responsible for binding to Axin and activation of the canonical/β-catenin pathway, while the DEP domain functions only in the non-canonical Wnt pathway and is responsible for activation of the small GTPases, Rho and Rac (18).

Mutations in the genes encoding components of Wnt signaling pathways have been found in many human cancers, notably colorectal cancer (13, 19). Mutations in axin, β-catenin and APC are found in sporadic medulloblastomas along with nuclear localization of β-catenin, suggesting constitutive Wnt signaling (20-22). Wnt signaling through the canonical β-catenin pathway has also been reported to increase the stem-like behavior of astrocytes and glioma cell lines, while downregulation of canonical Wnt/ β-catenin pathway induces apoptosis in glioma cell lines (23, 24). High expression levels of Dvl2 have so far been observed in both lung and colon cancer. Dvl overexpression has been shown to be critical for Wnt signaling in non-small cell lung cancer (25, 26). Dvl has also been implicated, together with mTOR, in the progression of colorectal neoplasia (27).

In this study, we examine the role of Dvl in human gliomas. A tissue microarray analysis revealed Dvl2 overexpression in more than 70% of the analyzed GBM samples. Dvl2 depletion was found to block the proliferation of human gliomas and promote their differentiation both in vitro and in vivo. Finally, both canonical and non-canonical signaling pathways are required to maintain the proliferative capacity of glioma cells.


Animal experiments

Cells were infected with viral vectors and selected in puromycin as described below. 6-8 weeks old NOD/SCID female mice were stereotactically injected with 2×105 cells into the striatum under a Memorial Sloan-Kettering Animal Care Committee-approved protocol. The animals were imaged using Magnetic Resonance Imaging (MRI) at MSKCC animal imaging core facility. Mice were maintained until development of neurologic signs and then sacrificed and perfusion-fixed with 4% para-formaldehyde (PFA). The brains were post-fixed for 24h in 4% PFA, incubated in 30% sucrose and then snap frozen in Optimal Cutting Temperature (OCT) compound and cut on a cryostat (coronal sections, 25μM). Standard protocols were used for Hematoxylin-Eosin staining. Immunofluorescence staining was performed as described in the section “Immunofluorescence staining”.

Tissue microarray and tumor samples

For analysis of Dvl2 levels by immunohistochemistry, a tissue microarray (TMA) containing glioblastoma and normal brain samples was used (US Biomax, GL806). The TMA contains 35 cases of glioblastoma and 5 normal brain tissues, represented as duplicate cores per case. The immunohistochemical detection of Dvl2 was performed at the Molecular Cytology Core Facility of Memorial Sloan Kettering Cancer Center using Discovery XT processor (Ventana Medical Systems). Tissue sections were blocked for 30 minutes in 10% normal goat serum in 0.2% BSA/PBS, followed by incubation for 5h with 10 μg/ml of the primary antibody (rabbit polyclonal anti-Dvl-2; Chemicon cat# ab5972 lot# j61682917) and incubation for 60 min with biotinylated goat anti-rabbit IgG (Vector labs, cat#:PK6101; 1:200 dilution). The detection was performed with DAB-MAP kit (Ventana Medical Systems). The glioblastoma samples for western blot analysis were collected from patients undergoing surgery at Memorial Sloan-Kettering Cancer Center, with consent. Normal tissue was obtained from a small cortical area removed during the surgical approach. The samples were snap frozen in liquid nitrogen, triturated using a plastic pestle and then collected in lysis buffer as described (see Protein analysis in Supplemental Material).

Cell lines and human GBMs

The human glioma cell lines U87, U138, U373 and U251 were cultured in MEM Gluta-Max (Gibco, 41090) supplemented with 10% FCS, 10mM Hepes, non-essential amino acids (Gibco, 11140) and antibiotics. LN229 were cultured in DME supplemented with 5% FCS and antibiotics. Primary glioblastoma samples were derived form patients undergoing surgery at Memorial Sloan-Kettering Cancer Center. Primary GBM samples were dissociated as described by Pollard and colleagues and grown as a monolayer on plastic cell culture dishes coated with 10ng/ml laminin (Sigma, L2020) (28). All patient-derived cells were cultured in NeuroCult NS-A basal medium, human (StemCell Technology, 05750), supplemented with NeuroCult NS-A proliferation supplements, human (StemCell Technology, 05754) and 10ng/ml human bFGF (Sigma F0291) and 20ng/ml human EGF (Prepotech AF-100-15) (In the main text we refer to this medium as neural stem cell medium for simplicity). For differentiation, primary GBM cells were plated on 10ng/ml laminin and the NeuroCult NS-A basal medium was replaced with MEM GlutaMax 5% FCS 48h before the infection.

Growth curve and neurosphere formation assay

Cells were infected with control or Dvl2 shRNAs and selected in 1μg/ml puromycin for 5d. 2×104 cells were plated per well in a 12-well plate and each sample was plated in triplicate. For glioma cell lines growing in 10% FCS, cell number was counted after 3d, 5d and 7d. Primary GBM cells were plated on laminin-coated dishes and grown as an adherent monolayer in serum-free neural stem cell medium. Cells were counted after 4d, 8d and 16d. For neurosphere formation, cells were grown and infected in an adherent monolayer in neural stem cell medium. After puromycin selection, cells were resuspended and grown in neural stem cell medium containing 0.7% methylcellulose (9). 5×103 cells were plated in each well of a 24-well plate in quadruplicate. The number of neurospheres with a diameter greater than 50μm was counted after 10d or 15d, for U87 or primary GBMs respectively.

Immunofluorescence analysis

Cells were plated on glass coverslips coated with laminin and infected with viral vectors as described above. After selection, cells were fixed in 4% formaldehyde, rinsed three times in PBS 1x and permeabilized in PBS containing 0.3% Triton and 10% goat serum. Samples were incubated overnight at 4°C with the primary antibody and 45min at room temperature with the secondary antibody and with Hoechst. Mouse brain cryo-sections were stained following the same procedure. For fluorescence imaging, images were taken using 10x or 20x objective lenses on a Zeiss Axio Imager.A1 microscope. The following antibodies were used: mouse anti-Nestin (Abcam ab22035, 1:100), mouse anti Tuj1 (Millipore MAB1637, 1:250), rabbit anti-GFAP (DAKO Z0334, 1:1000). For actin cytoskeleton detection Alexa 546-conjugated phalloidin was used (Invitrogen A22283, 1:100). Apoptosis was detected on fixed cells using the In Situ Cell Death detection kit (Roche, 11684795910), according to the manufacturer’s instructions. Senescence was detected using the Senescence ß-galactosidase kit (Cell Signaling, 9860S), following the manufacturer’s instructions.

Statistical analysis

Statistical analysis was performed using Microsoft Excel 2008. Student’s t-test (2-tailed, unpaired) was used to determine the significance of results comparing cells infected with shControl and Dvl2 shRNA. Wilcoxon-Mann-Withney Test was used to determine the significance of the in vivo tumor growth. *P<0.05, **P<0.01, ***P<0.001


Endogenous Dishevelled is expressed at high levels in human glioblastomas

Overexpression of Dvl has been shown to potentiate the activation of Wnt signaling pathways (29, 30). To examine the potential role of Wnt signaling in high-grade brain tumors, we first compared the expression levels of Dvl2 (the most widely expressed isoform of Dishevelled) in normal and cancer brain tissues using the Oncomine database. Analysis based on a set of data including 80 glioblastoma samples showed that the levels of Dvl2 mRNA were increased in brain cancer tissue compared to normal tissue (Figure 1A) (31). The Cancer Genome Atlas (TCGA) data set was also analyzed for Dvl2 expression in brain cancer but the results appeared not significant (P=1.000; not shown). The level of Dvl2 protein was next analyzed in a group of 10, freshly-derived GBM samples. As shown in Figure 1B, Dvl2 is overexpressed, though to different extents, in all patient samples, when compared to normal brain tissue. EGF receptor (EGFR) overexpression and p53 loss are commonly found in human GBMs, but no significant correlation was found between Dvl2 and either EGFR or p53 expression (Figure 1B) (2, 32, 33). We also analyzed the status of isocitrate dehydrogenase-1 (IDH1) gene in these freshly-derived samples (34). As shown in supplementary Fig.1, only one sample showed a mutation in IDH1, the mutation being the less common R132G.

Figure 1
Dvl2 is overexpressed in human glioblastomas

To further investigate the expression levels of Dvl2 in high-grade gliomas, a tissue microarray (TMA) containing 35 samples from patients diagnosed with grade IV glioma and 5 control brain samples was examined using a Dvl2-specific antibody. Tumors were scored as negative (0), medium positive (1), or very positive (2). Dvl2 is overexpressed in more than 70% of the GBM samples, with around 20% of these showing very high levels (Figure 1C). We conclude that Dvl2 is overexpressed in a significant number of human GBM samples, raising the possibility that Wnt signaling plays an important role in these tumors.

Dishevelled depletion blocks proliferation and induces differentiation of U87 glioma cells

To explore the role of Wnt signaling in human GBM, lentiviral shRNA vectors targeting Dvl2, which is essential for all known Wnt signaling pathways, were obtained (14). The glioma cell line U87, originally derived from a human glioblastoma, harbors mutations in PTEN and p16ink4a, and is highly proliferative and tumorigenic both in vivo and in vitro. Two different lentiviral constructs, which efficiently deplete Dvl2 in these cells significantly inhibited their proliferation (Figure 2A,B). This was associated with an increase in the cell cycle inhibitor p21WAF (Figure 2B), a decrease in BrdU incorporation (Figure 2C) and inhibition of anchorage independent growth (Supplemental Figure 2A,B). The proliferation block associated with Dvl2 depletion was not accompanied by apoptotic death or senescence (Supplemental Figure 3A,B).

Figure 2
Dvl2 depletion blocks proliferation and induces differentiation of U87 glioma cells

Time-lapse video microscopy (Figure 2D and Supplemental Movies 1 and 2), revealed a dramatic change in cell morphology induced around 72h after Dvl2 depletion. Control cells (infected with non-targeting shRNA lentivirus) remain highly motile and undergo cell divisions as expected (Supplemental Movie 1), but Dvl2-depleted cells become flat and non-motile, and elaborate elongated processes reminiscent of a differentiated state (Figure 2D, black arrows and Supplemental Movie 2). Western blot and immunofluorescence analysis revealed that Dvl2 depletion leads to a decrease in Nestin (a marker for neural stem/progenitor cells), an increase in Tuj1 (a neuronal marker) and a modest increase in GFAP (an astrocytic marker) (Figure 2E,F and Supplemental Fig.4) consistent with the induction of a differentiation-like program.

Since differentiation of stem/progenitor cells is associated with the loss of self-renewal, the impact of Dvl2 depletion on neurosphere formation was examined. The formation of non-adherent neurospheres, in serum-free media supplemented with EGF and FGF, is a widely recognized property of neural stem cells and is commonly used as an in vitro surrogate for self-renewal or stem cell-like properties (35). U87 cells efficiently form neurospheres after 10d of culture in neural stem cell medium, but this is dramatically reduced after Dvl2 depletion (Figure 2G-H). These data indicate that Dvl2 is necessary for the proliferation of U87 glioma cells and that Wnt signaling pathways have a role in regulating the neurosphere forming ability of these cells.

To confirm the specificity of RNAi depletion, rescue experiments were performed using a mouse Dvl2 (mDvl2) construct that is resistant to the sh2 lentivirus. A partial rescue of the proliferation defect and associated downregulation of p21WAF was observed (Figure 3A,C). In addition, a partial rescue of differentiation was observed, with increased Nestin expression and decreased Tuj1 expression (Figure 3A,B). Consistent with these findings, overexpressing of Dvl2 in U87 cells resulted in an increase in Nestin expression levels together with an increase in proliferation and neurosphere formation (Supplemental Figure 6A-C).

Figure 3
Expression of mouse Dvl2 rescues the differentiation-like phenotype in U87 glioma cells

To explore the wider significance of Dvl2 in human glioblastoma, four additional cell lines, U373, U138, LN229 and U251, each carrying different genetic mutations were infected with an shRNA lentiviral vector (36). Dvl2 depletion inhibited the proliferation of all four lines in serum cultures and in anchorage independent growth assays (Supplemental Figure 7A,B), while p21WAF protein levels were increased in 3 of the 4 lines (Supplemental Figure 7C).

Dishevelled depletion induces the differentiation of primary, patient-derived glioblastoma cultures

To determine whether Dvl2 plays an important role in primary human glioblastoma (GBM), freshly derived tumor samples were obtained from three individual patients (GBM1/GBM2/GBM3) (Supplemental Table 1, Supplemental Fig.5). Tumors were dissociated and grown as adherent cultures on laminin coated dishes (28). GBM cells were then infected with lentiviral shRNA vectors targeting Dvl2 or a control shRNA. Dvl2 depletion inhibited the proliferation of all three GBMs in serum cultures (Figure 4), as well as their ability to grow as neurospheres in neural stem cell medium (Figure 5H). All three GBMs underwent significant morphological changes reminiscent of differentiation, together with down-regulation of Nestin and up-regulation of the glial marker GFAP (Figure 5A-G). A significant increase in p21WAF and Tuj1 was also seen by western blot in 2 out of 3 samples (Figure 5G). We conclude that Dvl2-mediated signaling is required to maintain the self-renewal ability of both glioma cell lines and patient-derived GBM samples.

Figure 4
Dvl2 depletion blocks proliferation of patient-derived primary GBMs
Figure 5
Dvl2 depletion blocks neurosphere formation and promotes differentiation of patient-derived primary GBMs

Dishevelled depletion inhibits glioblastoma tumorigenicity in vivo

To determine whether Dvl2 depletion is effective at suppressing in vivo tumorigenicity, intra-cranial injections of controls, or tumor cells originating from a patient tumor (GBM1), or cell lines (including a GFP-U87 line) expressing Dvl2 shRNA were performed in NOD/SCID mice (for a total of 8 control mice and 12 mice injected with Dvl2-depleted cells). Magnetic resonance imaging (MRI) performed 13 weeks after injection of cells derived from patient GBM1 revealed an extensive and invasive tumor mass (Figure 6A). However, GBM1 cells that had been infected with Dvl2 shRNA lentivirus 7d prior to intra-cranial injection did not produce tumors detectable by MRI or histology at this time (Figure 6A). In one out of 3 mice injected with Dvl2 depleted GBM1, a small lesion was detectable by MRI at 21 weeks after injection (not shown; the animal was left alive for 25 weeks). Overall, the absence of tumor mass was reflected in the survival curve, indicating that Dishevelled signaling is critical for glioma development in vivo (Figure 6F). To investigate the fate of Dvl2-depleted GBM1 cells in vivo, brain cryo-sections were obtained. Immunohistological studies showed a highly proliferative tumor mass in mice injected with control, but not Dvl2- depleted cells (Figure 6B). Similarly, using an antibody specific for human Nestin, rare human GBM1 cells were found at the Dvl2 depleted injection sites (Figure 6C). The small lesion found in one out of 12 mice injected with Dvl2-depleted cells, was positive for human Nestin (not shown).

Figure 6
Dvl2 depletion suppresses tumorigenicity of primary GBM cells

To determine whether Dvl2-depleted cells die after injection, or adopt a differentiated phenotype and integrate into the mouse brain, a GFP-expressing U87 cell line (U87-GFP) was generated. Control cells (U87-GFP) generated a tumor 5 weeks after intra-cranial injection, while Dvl2-depleted U87-GFP cells induced no lesions detectable by MRI up to 20 weeks after injection (Figure 6G, Supplemental Figure 8A,B). Subsequent analysis of brain cryo-sections for GFAP (an astrocytic differentiation marker) and GFP, revealed cells that had infiltrated the mouse brain and were positive for both (Figure 6D,E, arrows). This result indicates that the injected Dvl2 depleted cells are still present in the mouse brain, and some adopt a differentiate-like state (Figure 6D,E).

Canonical and non-canonical Wnt signaling pathways cooperate in the regulation of glioblastoma cell proliferation

Although different Wnt ligands can activate distinct signal transduction pathways, Dishevelled is thought to be essential in all cases (14). To begin to explore the nature of Dvl2 signaling in gliomblastoma, we used U87 cells. siRNA oligonucleotides were used to deplete β-catenin, an essential component of the canonical Wnt signaling pathway. Despite a relatively modest RNAi knockdown (Figure 7B), β-catenin depletion strongly inhibited the proliferation of U87 cells in culture (Figure 7A). However, it did not induce differentiation, as judged by morphology or protein markers (p21WAF/Nestin/Tuj1) (Figure 7B; Supplemental Figure 9B). As an alternative approach to inhibit canonical Wnt signaling, a truncated (dominant negative) form of the transcription factor TCF-4 (DN-TCF), previously shown to block β-catenin mediated transcription, was used (37, 38). This also inhibited the proliferation of U87 cells (Figure 7A), but did not induce any differentiation markers (Figure 7B; Supplemental Figure 9C). To further investigate the role of canonical Wnt/β-catenin signaling in the Dvl-dependent differentiation event, we used a non-phosphorylatable/active form of β-catenin. If the block of canonical Wnt/β-catenin signaling is responsible for the differentiation-like phenotype caused by Dvl2 depletion, an active form of β-catenin should be able to rescue this effect. As shown in Supplemental Figure 10, U87 cells stably expressing active β-catenin (β-catenin with serine to alanine substitutions at position 35, 37, 41 and 45, or β-catenin-S4A) were not able to rescue the proliferation block or the differentiation phenotype caused by Dvl2 depletion. We conclude that β-catenin-mediated, canonical Wnt signaling is required to maintain the proliferative capacity of human glioblastoma cells, as suggested by others (23). However, since loss of β-catenin/TCF-4 does not phenocopy the loss of Dvl2, and active β-catenin does not restore the normal proliferative behavior of these cells, we conclude that additional signals downstream of Dvl2 are also involved.

Figure 7
Canonical and non-canonical Wnt signaling maintain glioma cell proliferation

To investigate the possible involvement of non-canonical Wnt signaling, lentiviral constructs encoding shRNAs targeting the non-canonical Wnt ligand Wnt5a were used. Depletion of Wnt5a with two different shRNAs inhibited the proliferation of both U87 cells and primary cells derived from patient GBM1 (Figure 7C-F), but was not able to induce differentiation (Figure 7G). Furthermore, Wnt5a depleted cells become flat and show high levels of ß-galactosidase, a known marker of cellular senescence (Figure 7H). Finally, depletion of Wnt5a dramatically inhibited the ability of primary GBM1 cells to form neurospheres in neural stem cell medium (Figure 7F). These results suggest a role for a non-canonical Wnt pathway in regulating glioma cell proliferation.


To explore the role of Wnt signaling in human glioblastoma, Dvl2, a key downstream component of all known Wnt signaling pathways, was depleted using RNAi. Dvl2 depletion not only inhibited the proliferation, but also promoted the differentiation of human glioma cell lines as well as freshly-derived patient glioblastoma samples. Dvl2 depletion inhibited neurosphere formation, an assay for the cancer stem-like subpopulation, as well as tumorigenicity, after intracranial injections in the mouse. Surprisingly, however, inhibition of the canonical Wnt signaling pathway, by β-catenin depletion, or expression of a dominant negative version of the TCF transcription factor, blocked proliferation, but did not induce differentiation. We have gone on to show that a non-canonical Wnt signaling pathway, involving the ligand Wnt5a, is also required to maintain the proliferative capacity of human glioblastoma cells. We conclude that a combination of canonical and non-canonical Wnt signaling is required to maintain glioblastoma proliferation.

Human glioblastomas are associated with a variety of genetic changes, including mutations in PTEN, EGFR, PDGFR, p53 and p16INK4a, and their contribution to disease development has been explored experimentally using mouse models (2, 39). Overexpression of PDGFR in neural progenitors, for example, induces the formation of oligodendrogliomas (40), while inactivation of both p53 and PTEN prevents neural stem/progenitor cell differentiation, in part at least through upregulation of c-myc, and leads to the generation of malignant glioma (41). Other major signaling pathways involved in the regulation of neural stem cells have been reported to be altered in gliomas, including Notch and Hedgehog (42). In fact, mutations in the Hedgehog signaling pathway have been found in another brain cancer, medulloblastoma, and inhibition of this pathway blocks the proliferation and self-renewal of stem-like glioma cells (43). Canonical Wnt signaling is a major player in maintaining the self-renewal capacity of neural stem cells and has been reported to be upregulated in brain cancers, including glioma (10, 44, 45). A recent report identified PLAGL2 as a glioma oncogene and showed that it exerts its effects by promoting canonical Wnt signaling to suppress differentiation and promote self-renewal of neural stem/progenitor cells (23).

Here we show for the first time that Dvl2 is overexpressed in high-grade gliomas, suggesting a role for active Wnt signaling in regulating the biology of these tumors. Despite the different amplification levels of EGFR, or p53 status, in the various cell lines and GBM cells used in this study, Dvl2 depletion induces a block of proliferation and a morphological change that has the characteristics of a differentiation-like phenotype. The fact that this phenotype was not observed upon a block of Wnt/β-catenin pathway, suggests that more than just the well-characterized canonical Wnt signaling is involved downstream to Dvl in this process.

Mutations in components of non-canonical Wnt signaling have not been reported so far in human gliomas, though expression of the non-canonical Wnt ligand, Wnt5a, has been reported to increase with glioma grade (24, 46). We report here that depletion of Wnt5a blocks proliferation and induces senescence of glioma cells, showing that a non-canoncial Wnt signaling pathway is required to maintain the proliferative capacity of glioma cells. Therefore, we demonstrate that both canonical and non-canonical Wnt signaling pathways maintain the proliferative capacity of human glioblastoma cells. Since loss of Dvl2 not only inhibits proliferation, but also promotes a differentiation-like program, we conclude that inhibition of both Wnt signaling pathways might be required to initiate differentiation, though it possible that other signaling pathways downstream to Dvl2 are also involved. The identification of Wnt5a as an essential player in maintaining the proliferative capacity of glioma cells may provide new therapeutic opportunities for treating this disease.

Supplementary Material


We thank Dr. Jeremy Rich, Dr. Angelo Vescovi, Dr. Tania Maffucci and members of the Hall laboratory for many constructive discussions. We thank Dr. E. R. Fearon for the DN-TCF4 construct. We thank the High-Throughput Screening core facility at MSKCC for providing the shRNAs clones. We thank Dr. K. Manova-Todorova and Dr. A. Baldys at the Molecular Cytology Core Facility at MSKCC (Support Grant NCI P30-CA008748) for the TMA staining. We thank the Animal Imaging core facility at MSKCC for the Magnetic Resonance Imaging. This study is dedicated to Agata Annino, a dear colleague who died of brain cancer at the age of 32.

GRANT SUPPORT The work was supported by a National Institutes of Health (NIH) grant GM081435 to A. H. and a National Cancer Institute core center grant (P30-CA 08748). T.P. was supported in part by an American Italian Cancer Foundation Fellowship and an MSKCC Brain Tumor Center award.


Conflict of Interest: The authors declare no financial conflict of interests.


1. Huse JT, Holland EC. Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma. Nat Rev Cancer. 2010;10:319–31. [PubMed]
2. Ohgaki H, Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. 2007;170:1445–53. [PubMed]
3. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, et al. Identification of human brain tumour initiating cells. Nature. 2004;432:396–401. [PubMed]
4. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755–68. [PubMed]
5. Persson AI, Weiss WA. The side story of stem-like glioma cells. Cell Stem Cell. 2009;4:191–2. [PubMed]
6. Galli R, Binda E, Orfanelli U, Cipelletti B, Gritti A, De Vitis S, et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004;64:7011–21. [PubMed]
7. Gilbertson RJ, Rich JN. Making a tumour’s bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 2007;7:733–6. [PubMed]
8. Nusse R. Wnt signaling and stem cell control. Cell Res. 2008;18:523–7. [PubMed]
9. Gritti A, Frölichsthal-Schoeller P, Galli R, Parati EA, Cova L, Pagano SF, et al. Epidermal and fibroblast growth factors behave as mitogenic regulators for a single multipotent stem cell-like population from the subventricular region of the adult mouse forebrain. J Neurosci. 1999;19:3287–97. [PubMed]
10. Kalani MY, Cheshier SH, Cord BJ, Bababeygy SR, Vogel H, Weissman IL, et al. Wnt-mediated self-renewal of neural stem/progenitor cells. Proc Natl Acad Sci U S A. 2008;105:16970–5. [PubMed]
11. Cadigan KM, Liu YI. Wnt signaling: complexity at the surface. J Cell Sci. 2006;119:395–402. [PubMed]
12. Fearon ER, Cadigan KM. Cell biology. Wnt signaling glows with RNAi. Science. 2005;308:801–3. [PubMed]
13. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol. 2004;20:781–810. [PubMed]
14. Wallingford JB, Habas R. The developmental biology of Dishevelled: an enigmatic protein governing cell fate and cell polarity. Development. 2005;132:4421–36. [PubMed]
15. Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006;127:469–80. [PubMed]
16. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009;10:468–77. [PubMed]
17. Gao C, Chen YG. Dishevelled: The hub of Wnt signaling. Cell Signal. 2010;22:717–27. [PubMed]
18. Wharton KA. Runnin’ with the Dvl: proteins that associate with Dsh/Dvl and their significance to Wnt signal transduction. Dev Biol. 2003;253:1–17. [PubMed]
19. Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature. 2005;434:843–50. [PubMed]
20. Huang H, Mahler-Araujo BM, Sankila A, Chimelli L, Yonekawa Y, Kleihues P, et al. APC mutations in sporadic medulloblastomas. Am J Pathol. 2000;156:433–7. [PubMed]
21. Baeza N, Masuoka J, Kleihues P, Ohgaki H. AXIN1 mutations but not deletions in cerebellar medulloblastomas. Oncogene. 2003;22:632–6. [PubMed]
22. Yokota N, Nishizawa S, Ohta S, Date H, Sugimura H, Namba H, et al. Role of Wnt pathway in medulloblastoma oncogenesis. Int J Cancer. 2002;101:198–201. [PubMed]
23. Zheng H, Ying H, Wiedemeyer R, Yan H, Quayle SN, Ivanova EV, et al. PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell. 2010;17:497–509. [PMC free article] [PubMed]
24. Pu P, Zhang Z, Kang C, Jiang R, Jia Z, Wang G, et al. Downregulation of Wnt2 and beta-catenin by siRNA suppresses malignant glioma cell growth. Cancer Gene Ther. 2009;16:351–61. [PubMed]
25. Uematsu K, He B, You L, Xu Z, McCormick F, Jablons DM. Activation of the Wnt pathway in non small cell lung cancer: evidence of dishevelled overexpression. Oncogene. 2003;22:7218–21. [PubMed]
26. Uematsu K, Kanazawa S, You L, He B, Xu Z, Li K, et al. Wnt pathway activation in mesothelioma: evidence of Dishevelled overexpression and transcriptional activity of beta-catenin. Cancer Res. 2003;63:4547–51. [PubMed]
27. Metcalfe C, Ibrahim AE, Graeb M, de la Roche M, Schwarz-Romond T, Fiedler M, et al. Dvl2 promotes intestinal length and neoplasia in the ApcMin mouse model for colorectal cancer. Cancer Res. 2010;70:6629–38. [PMC free article] [PubMed]
28. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, Russell R, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009;4:568–80. [PubMed]
29. Millar SE, Willert K, Salinas PC, Roelink H, Nusse R, Sussman DJ, et al. WNT signaling in the control of hair growth and structure. Dev Biol. 1999;207:133–49. [PubMed]
30. Lee YN, Gao Y, Wang HY. Differential mediation of the Wnt canonical pathway by mammalian Dishevelleds-1, -2, and -3. Cell Signal. 2008;20:443–52. [PMC free article] [PubMed]
31. Sun L, Hui AM, Su Q, Vortmeyer A, Kotliarov Y, Pastorino S, et al. Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell. 2006;9:287–300. [PubMed]
32. Ekstrand AJ, Sugawa N, James CD, Collins VP. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc Natl Acad Sci U S A. 1992;89:4309–13. [PubMed]
33. Watanabe K, Tachibana O, Sata K, Yonekawa Y, Kleihues P, Ohgaki H. Overexpression of the EGF receptor and p53 mutations are mutually exclusive in the evolution of primary and secondary glioblastomas. Brain Pathol. 1996;6:217–23. discussion 23-4. [PubMed]
34. Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321:1807–12. [PMC free article] [PubMed]
35. Jensen JB, Parmar M. Strengths and limitations of the neurosphere culture system. Mol Neurobiol. 2006;34:153–61. [PubMed]
36. Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 1999;9:469–79. [PubMed]
37. Kolligs FT, Hu G, Dang CV, Fearon ER. Neoplastic transformation of RK3E by mutant beta-catenin requires deregulation of Tcf/Lef transcription but not activation of c-myc expression. Mol Cell Biol. 1999;19:5696–706. [PMC free article] [PubMed]
38. Smalley MJ, Sara E, Paterson H, Naylor S, Cook D, Jayatilake H, et al. Interaction of axin and Dvl-2 proteins regulates Dvl-2-stimulated TCF-dependent transcription. EMBO J. 1999;18:2823–35. [PubMed]
39. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, et al. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001;15:1311–33. [PubMed]
40. Dai C, Celestino JC, Okada Y, Louis DN, Fuller GN, Holland EC. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev. 2001;15:1913–25. [PubMed]
41. Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature. 2008;455:1129–33. [PubMed]
42. Li Z, Wang H, Eyler CE, Rich JN. Turning cancer stem cells inside-out: an exploration of glioma stem cell signaling pathways. J Biol Chem. 2009 [PMC free article] [PubMed]
43. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol. 2007;17:165–72. [PMC free article] [PubMed]
44. Clark PA, Treisman DM, Ebben J, Kuo JS. Developmental signaling pathways in brain tumor-derived stem-like cells. Dev Dyn. 2007;236:3297–308. [PubMed]
45. Zhang Z, Schittenhelm J, Guo K, Buhring HJ, Trautmann K, Meyermann R, et al. Upregulation of frizzled 9 in astrocytomas. Neuropathol Appl Neurobiol. 2006;32:615–24. [PubMed]
46. Yu JM, Jun ES, Jung JS, Suh SY, Han JY, Kim JY, et al. Role of Wnt5a in the proliferation of human glioblastoma cells. Cancer Lett. 2007;257:172–81. [PubMed]